Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jason R. Jaroslavsky"'
Autor:
Christine D. Palmer, Ciaran D. Scallan, Lauren D. Kraemer Tardif, Melissa A. Kachura, Amy R. Rappaport, Daniel O. Koralek, Alison Uriel, Leonid Gitlin, Joshua Klein, Matthew J. Davis, Harshni Venkatraman, Meghan G. Hart, Jason R. Jaroslavsky, Sonia Kounlavouth, Martina Marrali, Charmaine N. Nganje, Kyounghwa Bae, Tiffany Yan, Katharyn Leodones, Milana Egorova, Sue-Jean Hong, Jenchun Kuan, Silvia Grappi, Pedro Garbes, Karin Jooss, Andrew Ustianowski
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-17 (2023)
Abstract SARS-CoV-2 has resulted in high levels of morbidity and mortality world-wide, and severe complications can occur in older populations. Humoral immunity induced by authorized vaccines wanes within 6 months, and frequent boosts may only offer
Externí odkaz:
https://doaj.org/article/a5bd0b01360c4ba2becb6b71a325f706
Autor:
Christine D. Palmer, Meghan G. Hart, Sonia Kounlavouth, Harshni Venkatraman, Lauren D. Kraemer, Martina Marrali, Calixto Dominguez, Fatema Z. Chowdhury, Jason R. Jaroslavsky, Lindsey Arcebuche, Lorenzo Hernandez, Bukola Adeoye, Severino Cuison, Amy R. Rappaport, Greg Boucher, Monica Lane, Melissa Rotunno, Kenneth Avocetien, Leiliane Sousa, Chris Puccia, Molly Likes, Rahul Vegesna, Rita Zhou, Alexis Mantilla, Matthew J. Davis, Ankur Dhanik, Melissa Johnson, Andrew R. Ferguson, Karin Jooss
Publikováno v:
Cancer Research. 83:2267-2267
Mutations in the KRAS gene are among the most common driver mutations in cancer. Targeting KRAS G12C mutations has shown some promise in clinical studies, though acquired resistance mutations pose a challenge for small molecule-based monotherapies. V
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93ad16672aa616f9fe27fb240af508cd
https://doi.org/10.1158/1538-7445.am2023-2267
https://doi.org/10.1158/1538-7445.am2023-2267
Autor:
Christine D. Palmer, Amy R. Rappaport, Matthew J. Davis, Meghan G. Hart, Ciaran D. Scallan, Sue-Jean Hong, Leonid Gitlin, Lauren D. Kraemer, Sonia Kounlavouth, Aaron Yang, Lindsey Smith, Desiree Schenk, Mojca Skoberne, Kiara Taquechel, Martina Marrali, Jason R. Jaroslavsky, Charmaine N. Nganje, Elizabeth Maloney, Rita Zhou, Daniel Navarro-Gomez, Adrienne C. Greene, Gijsbert Grotenbreg, Renee Greer, Wade Blair, Minh Duc Cao, Shawn Chan, Kyounghwa Bae, Alexander I. Spira, Sameek Roychowdhury, David P. Carbone, Brian S. Henick, Charles G. Drake, Benjamin J. Solomon, Daniel H. Ahn, Amit Mahipal, Steve B. Maron, Benny Johnson, Raphael Rousseau, Roman Yelensky, Chih-Yi Liao, Daniel V. T. Catenacci, Andrew Allen, Andrew R. Ferguson, Karin Jooss
Publikováno v:
Nature medicine. 28(8)
Checkpoint inhibitor (CPI) therapies provide limited benefit to patients with tumors of low immune reactivity. T cell-inducing vaccines hold promise to exert long-lasting disease control in combination with CPI therapy. Safety, tolerability and recom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52b98fe066b3154800e3b88b1ce6062d
https://pubmed.ncbi.nlm.nih.gov/35970920
https://pubmed.ncbi.nlm.nih.gov/35970920
Autor:
Christine D. Palmer, Amy R. Rappaport, Meghan G. Hart, Lauren D. Kraemer, Sonia Kounlavouth, Martina Marrali, Jason R. Jaroslavsky, Charmaine N. Nganje, Annie Shen, Gregory R. Boucher, Melissa A. Kachura, Ciaran D. Scallan, Sue-Jean Hong, Leonid Gitlin, Alexander I. Spira, Chrisann Kyi, Daniel V. Catenacci, Raphael Rousseau, Andrew Ferguson, Karin Jooss
Publikováno v:
Cancer Research. 82:4159-4159
The immunogenicity and efficacy of RNA-based vaccine platforms has been abundantly shown through their application in prophylactic SARS-CoV2 vaccines. Contrasting to mRNA based vectors, self amplifying mRNA platforms may offer dose-sparing and superi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62de1f445a85e4d28233716e3e9c26b2
https://doi.org/10.1158/1538-7445.am2022-4159
https://doi.org/10.1158/1538-7445.am2022-4159
Autor:
Amy R. Rappaport, Christine D. Palmer, Annie Shen, Claudia X. Dominguez, Meghan G. Hart, Lauren D. Kraemer, Sonia Koulavouth, Martina Marrali, Jason R. Jaroslavsky, Charmaine N. Nganje, Ciaran D. Scallan, Sue-Jean Hong, Leonid Gitlin, Monica Lane, Daniel V. Catenacci, Chrisann Kyi, David P. Carbone, Hossein Borghaei, Raphael Rousseau, Andrew Ferguson, Karin Jooss
Publikováno v:
Cancer Research. 82:3578-3578
Vaccines targeting neoantigens identified from common tumor driver mutations are of increasing interest as evidence of clinical benefit builds, and opportunities to combine such vaccines with immune modulators are growing. Our individualized neoantig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78232c5a27e1751e18dcb2e80be1b942
https://doi.org/10.1158/1538-7445.am2022-3578
https://doi.org/10.1158/1538-7445.am2022-3578